Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Taysha Gene Therapies (NASDAQ: TSHA) announced three oral presentations and a symposium at the 2025 IRSF Rett Syndrome Scientific Meeting in Boston from June 9-11, 2025. The presentations will cover clinical data from TSHA-102 trials, including high and low dose cohorts from REVEAL adolescent/adult and pediatric Phase 1/2 trials, caregiver research on developmental milestones, and preclinical data on AAV9 vector biodistribution. The company will also host a symposium on Rett syndrome natural history data findings. Dr. Sukumar Nagendran, President and Head of R&D, emphasized TSHA-102's potential to improve function and quality of life for Rett syndrome patients. The presentations align with FDA discussions on potential registration pathways and demonstrate the company's progress in developing gene therapy treatments for this severe CNS disorder.

Taysha Gene Therapies (NASDAQ: TSHA) has announced the pricing of a public offering, consisting of 46,868,687 shares of common stock at $2.75 per share and pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The company expects to raise approximately $200.0 million in gross proceeds before deducting expenses.

The underwriters have a 30-day option to purchase up to an additional 10,909,090 shares. The offering, led by joint book-running managers Jefferies, BofA Securities, Piper Sandler, and Barclays, is expected to close around May 30, 2025. Taysha is a clinical-stage biotechnology company developing AAV-based gene therapies for severe CNS monogenic diseases.

Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has announced a new public offering of common stock and pre-funded warrants. The offering includes an option for underwriters to purchase up to an additional 15% of shares within 30 days. Jefferies, BofA Securities, Piper Sandler, and Barclays are serving as joint book-running managers for the offering.

The offering will be conducted under a shelf registration statement that was filed with the SEC on December 13, 2024, and became effective on December 20, 2024. The final size, terms, and completion of the offering will depend on market conditions.

Taysha Gene Therapies (NASDAQ: TSHA) has announced pivotal trial design details for TSHA-102 in Rett syndrome, supported by FDA alignment and positive clinical data. The trial design is based on natural history data showing patients ≥6 years have a ~0% chance of gaining developmental milestones. Key highlights include:

The pivotal Part B trial will be a single-arm, open-label study (N=15) in patients ≥6 years old. Remarkably, Part A results showed 100% of patients (N=10) gained/regained ≥1 developmental milestone post-treatment, with the high dose showing superior results compared to low dose.

The treatment has been well-tolerated with no treatment-related serious adverse events. The company plans to submit the pivotal trial protocol this quarter and initiate the trial in Q3 2025. The trial's primary endpoint will assess developmental milestone gain/regain, with patients serving as their own control.

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 2025 financial results and provided updates on its TSHA-102 program for Rett syndrome. The company received FDA alignment on pivotal Part B trial design, allowing direct submission of the trial protocol as an IND amendment in Q2 2025, potentially expediting study initiation. Safety data shows both high dose (1x1015 vg) and low dose (5.7x1014 vg) of TSHA-102 are well-tolerated with no treatment-related SAEs or DLTs in 10 patients across REVEAL trials. Financially, Q1 2025 showed R&D expenses of $15.6M (down from $20.7M in Q1 2024), net loss of $21.5M ($0.08 per share), and cash position of $116.6M, expected to fund operations into Q4 2026. The company will present three oral presentations at the upcoming IRSF Rett Syndrome Scientific Meeting in June 2025.

Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has scheduled its Q1 2025 financial results release and corporate update for May 15, 2025, at 8:30 AM ET. The company will host a conference call and webcast accessible via toll-free and international dial-in numbers, with a dedicated conference ID. Investors and interested parties can also access the webcast through Taysha's investor relations website.

Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The Compensation Committee approved an option to purchase 45,000 shares of common stock under the company's 2023 Inducement Plan. The option has an exercise price of $2.41, matching the closing price on the grant date. The stock option features a 10-year term with a four-year vesting schedule: 25% vests after the first year, followed by monthly vesting of the remaining 75% over 36 months. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has announced new stock option grants. The Compensation Committee approved options for 822,000 shares to five new employees on April 1, 2025, under the company's 2023 Inducement Plan.

The options were granted at an exercise price of $1.265, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.

Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has granted stock options to three new employees. The Compensation Committee approved options to purchase 225,000 shares of common stock on March 3, 2025, under the company's 2023 Inducement Plan.

The options were granted at an exercise price of $1.62 per share, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.